Clozapine-Associated Pulmonary Embolism: A High-Mortality, Dose-Independent and Early-Onset Adverse Effect

@article{Sarvaiya2018ClozapineAssociatedPE,
  title={Clozapine-Associated Pulmonary Embolism: A High-Mortality, Dose-Independent and Early-Onset Adverse Effect},
  author={Nilofar Sarvaiya and Yevgeniya Lapitskaya and Lorena Dima and Peter Manu},
  journal={American Journal of Therapeutics},
  year={2018},
  volume={25},
  pages={e434–e438}
}
Background: Recent epidemiological studies have identified an excess of pulmonary embolism (PE) cases in patients treated with antipsychotic drugs. The findings are particularly relevant for patients treated with clozapine, which has many potentially life-threatening adverse drug effects. Among these adverse drug effects are myocarditis and agranulocytosis that have early onset and are dose independent, but also seizures and myocardial repolarization delay, which are dose dependent and may… Expand
Clozapine associated pulmonary embolism: systematic review
TLDR
PE can occur at doses lower than usual dose of clozapine (300 mg daily), it is important to consider this association especially in patients with no other risk factors for PE. Expand
Clozapine-Related Thromboembolic Events
TLDR
It is observed that among clozapine users, VTE occurred at a wide dose range, and most of the events occurred within the first six months, and the risk should be considered at the time of prescribing. Expand
Clozapine-induced pulmonary embolism in a patient with minimal pre-existing risk factors.
TLDR
A case of antipsychotic-induced venous thromboembolism despite the patient's low-risk status is presented so that practitioners may better understand which factors may or may not constitute a major risk in this population when making a determination about prophylactic anticoagulation. Expand
Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals
TLDR
There is a need for better management of serious clozapine-related adverse events in addition to agranulocytosis, and better education of patients and carers, general practitioners, A&E and ITU staff and others of the problems posed in using clozAPine safely. Expand
The association and influencing factors between antipsychotics exposure and the risk of VTE and PE: a systematic review and meta-analysis.
TLDR
A meta-analysis showed that patients taking the first- or second-generation antipsychotics had a higher risk of venous thromboembolism and pulmonary embolism than those who did not, and low potency first-generation agents increased the risk more than high potency antipsychotic agents. Expand
Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review
TLDR
During clozapine initiation, fever is most frequently benign and transient but should be closely monitored as it may be the first stage of potentially life-threatening adverse drug reactions (ADR) (agranulocytosis, neuroleptic malignant syndrome myocarditis, hepatitis, pancreatitis, nephritis, colitis). Expand
Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19
TLDR
Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available and the genetic vulnerability postulates predictors of adverse reactions’ severity; patients with a lower genetic risk could have less frequent hematological monitoring. Expand
Clozapine. Pharmacodynamic Mechanisms, Potential Pharmacogenetic Biomarkers, and Risks in Schizophrenia. Particularities in the Context of Covid-19. An Updated Overview
TLDR
The genetic vulnerability postulates predictors of adverse reactions severity so clozapine doses should be personalised for each patient based on pharmacogenetic testing; patients with a lower genetic risk may benefit from a more relaxed hematological monitoring schedule. Expand
Supportive and palliative care for people with respiratory problems and preexisting serious mental illness.
TLDR
Key priorities are identified to improve accessibility and inclusivity of respiratory care pathways for people living with serious mental illness to support early detection and proactive monitoring of respiratory problems to help reduce the risk of early mortality. Expand
Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders
The acute management of agitated and aggressive behavior can be addressed with the use of verbal de-escalation techniques and the emergency use of antipsychotic medications, with or withoutExpand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Fatal Venous Thromboembolism Associated with Antipsychotic Therapy
TLDR
A 47-year-old woman treated with clozapine and paroxetine was admitted to the hospital with dyspnea and swelling of the leg and on hospital day 7, sudden acute respiratory failure developed and the patient died, postmortem examination confirmed the existence of massive PE. Expand
A case of cardiac arrest and pulmonary embolism after clozapine titration.
TLDR
A case in which a patient was started on clozapine treatment and subsequently developed pericardial tamponade and cardiac arrest complicated by pulmonary embolism is described, consistent with previously described cases of clozAPine-related cardiopulmonary complications that include polyserositis. Expand
Clozapine and pulmonary embolism
TLDR
A patient with a previous history of pulmonary embolism who developed a new episode of pulmonaryembolism shortly after clozapine treatment was initiated is described, which confirmed a diagnosis of multiple pulmonary emboli. Expand
Clozapine-Induced Pulmonary Embolism: A Case Report and Literature Review
TLDR
It was concluded that clozapine alone was the cause of pulmonary embolism in this patient and the role of nicotine remains questionable. Expand
Late onset myocarditis with clozapine use
TLDR
These cases meet the criteria for clozapine-related myocarditis but occur outside the initial high-risk period following commencement (Ronaldson et al., 2010), suggesting the need for ongoing clinical vigilance for symptoms suggestive of myocardritis for the duration of clozAPine treatment. Expand
Clozapine and venous thromboembolism: further evidence.
TLDR
He recovered well, from his psychosis as well as from the pulmonary embolism, and no new episodes of VTE have occurred after 4 years of treatment with clozapine and acenocoumarol. Expand
Nonfatal pulmonary embolus associated with clozapine treatment: a case series.
TLDR
Three patients treated with clozapine on a long-term inpatient unit that developed nonfatal pulmonary emboli (PE) and deep venous thrombosis (DVT) are reported on. Expand
A case report of clozapine continuation after pulmonary embolism in the context of other risk factors for thromboembolism
TLDR
It is important that emergency staff consider emerging psychosis as a potential diagnosis, and it is essential that in those individuals, management aligns with NICE recommendations: antipsychotics should not be used in the neuroleptic-naïve and not in any young person (<16 years. Expand
A New Monitoring Protocol for Clozapine-Induced Myocarditis Based on an Analysis of 75 Cases and 94 Controls
TLDR
This protocol recommends active monitoring for 4 weeks, relying predominantly on troponin and C-reactive protein results, and encourages continuation of clozapine in the presence of mild illness, but defines a threshold for cessation. Expand
Clozapine: Taliking about Risks, Benefits, and Alternatives with Patients
Clozapine is a life-saving medication for many patients with schizophrenia, including those who have a schizophrenia spectrum disorder with suicidality or treatment-resistant disease, but clinicians'Expand
...
1
2
3
4
...